Arcutis Biotherapeutics Inc. (ARQT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ARQT scores 54 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars, the fundamental cash engine scores 9 of 20 (ROIC -3%; FCF yield -0.16%), indicating that current cash generation does not yet support the equity on a return-on-capital basis. Whale/13F flow scores 17 of 20 (institutional accumulation and options positioning), the strongest pillar and a signal of institutional interest. Insider conviction scores 6 of 20 (SEC Form 4 and Congressional PTR cluster flow), a weak reading. Macro regime fit scores 8 of 20 (Beta 1; sector sensitivity). Forensic balance sheet scores 14 of 20 (Altman Z 7.78; Piotroski F 6/9; Debt/Equity 0.57), a moderate reading.

For a prospective investor evaluating the stock today, the rating implies a clear tradeoff: institutional positioning is supportive, while the earnings and cash-flow base is negative and insider conviction is weak. Upside, per the rating's framework, would depend on the cash engine turning positive; the valuation tradeoff is that the forward P/E of 24 is being paid against negative trailing EPS of -0.13. The balance-sheet pillar offers some cushion, but the overall verdict is a weak-fundamentals reading.

Arcutis Biotherapeutics Inc. (ARQT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. The financials show revenue of $376.1M for FY 2025, per the SEC financials. Gross margin is 90.2%, per the market data.

Per the SEC financials, the company reported losses in all three periods, though operating losses narrowed substantially from FY 2023 to FY 2025 and revenue grew across the series. Per the market data, the operating margin is -3.3%, the net margin is -4.3%, and ROIC is -3%. Per the Roarable RQD rating, the Altman Z-Score is 7.78 and the Piotroski F-Score is 6 of 9, with Debt/Equity of 0.57. The balance sheet posture, per these figures, shows debt of $108.0M against cash of $42.9M in FY 2025.

Per the recent news wire, six items relate to ARQT. Three are flagged RED "RISK WATCH" items (a Yahoo Finance piece questioning whether the stock is still below fair value following fresh ZORYVE data, a Seeking Alpha piece framing ARQT as an emerging GARP stock, and a Yahoo Finance clinical-data piece). A Benzinga item on a share surge is also flagged RED. Two items are flagged GREEN "CATALYST": a ChartMill piece on undervaluation supported by growth and margins, and a GuruFocus piece reporting shares rallying to a 52-week high amid strong momentum. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are available in the source data.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that this absence means the rating cannot be traced through a supplier or customer network within the provided data.

• What specific products and revenue drivers account for the growth from $59.6M in FY 2023 to $376.1M in FY 2025?
• What is the trailing P/E and EV/EBITDA, which are not reported in the source data?
• What is the path to positive free cash flow given FY 2025 FCF of $-6.3M?
• What drove the FY 2023 debt level of $517.2M and how has it been reduced to $108.0M?
• What do the 13F, insider, and Congressional trade records specifically show, since the holders section is unavailable?